Hypertension Journal

Register      Login

VOLUME 2 , ISSUE 1 ( January-March, 2016 ) > List of Articles

RESEARCH ARTICLE

Hypertension in Patients with Chronic Kidney Disease

P Vijay Varma, M Rajasekara Chakravarthi, G Jyothsna

Keywords : Aldosterone,Angiotensin,Chronic,Hypertension,Kidney,Renin

Citation Information : Varma PV, Chakravarthi MR, Jyothsna G. Hypertension in Patients with Chronic Kidney Disease. Hypertens J 2016; 2 (1):28-34.

DOI: 10.5005/jp-journals-10043-0026

Published Online: 00-03-2016

Copyright Statement:  Copyright © 2016; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

How to cite this article

Varma PV, Chakravarthi MR, Jyothsna G. Hypertension in Patients with Chronic Kidney Disease. Hypertens J 2016;2(1):28-34.


PDF Share
  1. Epidemiology and risk factors of chronic kidney disease in India: results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrol 2013 May 28;14:114.
  2. Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of diet in renal disease study group. Am J Kidney Dis 1996 Dec;28(6):811-821.
  3. Treatment of hypertension: drug therapy. In: Kaplan NM, Flynn JT, editors. Clinical hypertension. 9th ed. Philadelphia: Lippincott Williams and Wilkins; 2006. p. 217-230.
  4. Mechanisms for the elevation of blood pressure in human renal disease. Preliminary report. Hypertension 1982 Nov-Dec;4(6):839-844.
  5. Regulation of arterial pressure in the anephric state. Circulation 1970 Sep;42(3):509-514.
  6. Salt sensitivity of blood pressure in chronic renal failure. Evidence for renal control of body fluid distribution in man. Hypertension 1982 Mar-Apr;4(2):190-197.
  7. Hypertension in chronic renal disease. Kidney Int 1982;22(6):702-712.
  8. The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int 1994 Feb;45(2):403-410.
  9. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007 Sep;3(9):486-492.
  10. Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization. Cardiovasc Res 2008 Jul 1;79(1):169-178.
  11. Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans. Circulation 2001 Oct 9;104(15):1805-1808.
  12. Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uraemia? Nephrol Dial Transplant 2000 Nov;15(11):1735-1738.
  13. Effect of renal sympathetic nerve stimulation on proximal water and sodium reabsorption. J Clin Invest 1976 Apr;57(4):1104-1107.
  14. Failure of renal dopamine response to salt loading in chronic renal disease. Br Med J (Clin Res Ed) 1983 Feb 12;286(6364):503-506.
  15. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 2005 May;115(5):1275-1280.
  16. Oxidative stress: oxidants and antioxidants. Exp Physiol 1997 Mar;82(2):291-295.
  17. Hydrogen peroxide induces intracellular calcium oscillations in human aortic endothelial cells. Circulation 1998 Jan 27;97(3):268-275.
  18. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992 Mar 7;339(8793):572-575.
  19. Osmoregulation of thirst and vasopressin release in severe chronic renal failure. Kidney Int 1991 Feb;39(2):395-400.
  20. Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. Kidney Int 1993 Mar;43(3):700-705.
  21. Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients. Nephrol Dial Transplant 1998 Nov;13(11):2877-2883.
  22. The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin-angiotensin-aldosterone system, oxidative stress and endogenous digitalis in the brain. Hypertens Res 2011 Nov;34(11):1147-1160.
  23. A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure. Clin Biochem 2005 Jan;38(1):36-45.
  24. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Inter Suppl 2012;2:337-414.
  25. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008 May;19(5):999-1007.
  26. Renal effects of smoking: potential mechanisms and perspectives. Nephrol Dial Transplant 2000 Jul;15(7):938-940.
  27. Weight loss and proteinuria. Contrib Nephrol 2006;151:221-229.
  28. Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? Kidney Int 2013 Mar; 83(3):377-383.
  29. Combination angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy: its role in clinical practice. J Clin Hypertens (Greenwich) 2003 Nov-Dec;5(6):414-420.
  30. Retarding the progression of chronic kidney disease with renin angiotensin system blockade. Ind J Nephrol 2012 Mar;22(2):108-115.
  31. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004 May;43(5 Suppl 1):S1-S290.
  32. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008 Aug 16;372(9638):547-553.
  33. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007 Feb 16;100(3):342-353.
  34. Carvedilol in hypertension treatment. Vasc Health Risk Manag 2008;4(1):23-30.
  35. Metabolic effects of carvedilolvsmetoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004 Nov 10;292(18):2227-2236.
  36. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009 Oct;32(10):1873-1879.
  37. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008 Jun 5;358(23):2433-2446.
  38. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012 Dec 6;367(23):2204-2213.
  39. Intradialytic hypertension: it is time to act. Nephron Clin Pract 2010;115(3):c182–c188.
  40. Association of blood pressure increases during hemodialysis with 2-year mortality in incident hemodialysis patients: a secondary analysis of the Dialysis Morbidity and Mortality Wave 2 Study. Am J Kidney Dis 2009 Nov;54(5):881-890.
  41. Antihypertensive agents in hemodialysis patients: a current perspective. Semin Dial 2010 May-Jun;23(3):290-297.
  42. Ischemic nephropathy: pathogenesis and treatment. Nefrologia 2012 Jul 17;32(4):432-438.
  43. Percutaneousrevascularization for ischemic nephropathy: the past, present, and future. Kidney Int 2013 Jan;83(1):28-40.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.